|本期目录/Table of Contents|

[1]薛兰凤,罗文辉,何兴祥,等.粪菌移植治疗非酒精性脂肪性肝病研究进展[J].传染病信息,2019,04:299-303.
 XUE Lan-feng,LUO Wen-Hui,HE Xing-xiang,et al.Advances in fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease[J].Infectious Disease Information,2019,04:299-303.
点击复制

粪菌移植治疗非酒精性脂肪性肝病研究进展(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2019年04期
页码:
299-303
栏目:
导向与述评
出版日期:
2019-09-12

文章信息/Info

Title:
Advances in fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease
文章编号:
1007-8134(2019)04-0299-05
作者:
薛兰凤罗文辉何兴祥张发明陈 羽
510080 广州,广东药科大学附属第一医院消化内科(薛兰凤、罗文辉、何兴祥、陈羽);210011,南京医科大学第二附属医院肠病中心(张发明)
Author(s):
XUE Lan-feng LUO Wen-Hui HE Xing-xiang ZHANG Fa-ming* CHEN Yu*
Department of Gastroenterology, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, China
*Corresponding author. ZHANG Fa-ming, E-mail: fzhang@njmu.edu.cn; CHEN Yu, E-mail: yuchen@gdpu.edu.cn  
关键词:
非酒精性脂肪性肝病肠道菌群粪菌移植肝- 肠轴分子机制
Keywords:
 non-alcoholic fatty liver disease intestinal bacteria fecal microbiota transplantation gut-liver axis molecular mechanism
分类号:
R37;R575 
DOI:
10.3969/j.issn.1007-8134.2019.04.003
文献标识码:
A
摘要:
非酒精性脂肪肝病(non-alcoholic fatty liver disease, NAFLD)的发病率在世界范围内呈明显上升趋势,由于目 前尚无确切的特效治疗方式,严重影响人类健康。近年来,越来越多的研究表明肠道菌群通过肝- 肠轴影响肝功能,肠道 菌群失调是NAFLD 发病的重要原因。因此,纠正肠道菌群失调,可以预防和减轻NAFLD 的发生、发展。粪菌移植(fecal microbiota transplantation, FMT)被认为是纠正肠道菌群失调最有效的方法,但其在NAFLD 中的治疗作用还未明确。此外, FMT 治疗NAFLD 的潜在分子机制也尚未阐明。本文就FMT 治疗NAFLD 的研究现状进行总结,并发掘其潜在的分子机制, 为FMT 作为治疗NAFLD 的有效手段提供理论支持。
Abstract:
The incidence of non-alcoholic fatty liver disease (NAFLD) is significantly rising worldwide, and seriously affects human health because there is no approved drug for the treatment of NAFLD currently. Recently, increasing studies have demonstrated that intestinal bacteria affect liver function through the gut-liver axis, and the imbalance of intestinal bacterial composition is the key cause in the pathogenesis of NAFLD. Correcting intestinal bacterial imbalance, therefore, may prevent the development and attenuate the progression of NAFLD. Fecal microbiota transplantation (FMT) is considered the most effective method to correct intestinal bacteria imbalance, but its therapeutic role in NAFLD has not been established. Moreover, the potential molecular mechanisms of FMT for NAFLD have not been elucidated. This paper summarizes the currently available research results on the therapeutic effects of FMT for NAFLD, and proposes the underlying molecular mechanisms, which provide theoretical support for FMT as a useful modality for the treatment of NAFLD.

参考文献/References


[1] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver diseases[J]. Hepatology, 2018, 67(1):328-357.
[2] Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease[J]. Diabet Med, 2010, 22(9):1129-1133.
[3] Byrne CD, Targher G. NAFLD: a multisystem disease[J]. J Hepatol, 2015, 62(1 Suppl):S47-S64.
[4] 黄红丽,周永健,郑啼婴,等. 肠道菌群在非酒精性脂肪性 肝病大鼠中的变化及意义[J]. 广东医学,2016,37(9):1283- 1286.
[5] 唐外姣,周本杰. 肠道菌群失调——非酒精性脂肪肝病治疗 新靶点[J]. 世界华人消化杂志,2017,25(22):2000-2006.
[6] 陈文翰,孙光裕,陈伟忠,等. 复合乳酸菌胶囊对非酒精性 脂肪性肝病患者肠道菌群及血脂影响的临床研究[J]. 中国 医学创新,2018,15(25):1-5.
[7] 刘嘉琪,周少明. 非酒精性脂肪性肝病肠道菌群的研究进展 [J]. 临床肝胆病杂志,2017,33(12):2453-2456.
[8] Zhou D, Pan Q, Shen F, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota[J]. Sci Rep, 2017,7(1):1529.
[9] Vaughn BP, Rank KM, Khoruts A. Fecal microbiota transplantaton: current status in treatment of GI and liver disease[J]. Clin Gastroenterol Hepatol, 2018, 17(2):353-361.
[10] DeFilipp Z, Hohmann E, Jenq RR, et al. Fecal microbiota transplantaton: restoring the injured microbiome after allogeneic hematopoietc cell transplantaton[J]. Biol Blood Marrow Transplant, 2019, 25(1):e17-e22.
[11] de Groot PF, Frissen MN, de Clercq NC, et al. Fecal microbiota transplantaton in metabolic syndrome: history, present and future [J]. Gut Microbes, 2017, 8(3):253-267.
[12] 顾长海. 重型肝炎十种并发症的防治[J]. 传染病信息, 1995,8(4):162-166.
[13] Wang WW, Zhang Y, Huang XB, et al. Fecal microbiota transplantation prevents hepatic encephalopathy in rats with carbon tetrachloride-induced acute hepatic dysfunction[J]. World J Gastroenterol, 2017, 23(38):6983-6994.
[14] Zhang F, Luo W, Shi Y, et al. Should we standardize the 1,700-year-old fecal microbiota transplantation?[J]. Am J Gastroenterol, 2012, 107(11):1755.
[15] Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections[J]. Am J Gastroenterol, 2013, 108(4):478-498.
[16] Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH[J]. Hepatology, 2013, 57(2):601-609.
[17] de Faria Ghetti F, Oliveira DG, de Oliveira JM, et al. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis[J]. Eur J Nutr, 2018, 57(3):861-876.
[18] Ye JZ, Li YT, Wu WR, et al. Dynamic alterations in the gut microbiota and metabolome during the development of methioninecholine- deficient diet-induced nonalcoholic steatohepatitis[J]. World J Gastroenterol, 2018, 24(23):2468-2481.
[19] Poeta M, Pierri L, Vajro P. Gut-liver axis derangement in nonalcoholic fatty liver disease[J]. Children (Basel), 2017, 4(8):66.
[20] Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(7):397-411.
[21] Le Roy T, Llopis M, Lepage P, et al. Intestinal microbiota determines development of nonalcoholic fatty liver disease in mice [J]. Gut, 2013, 62(12):1787-1794.
[22] Soderborg TK, Clark SE, Mulligan CE, et al. The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD[J]. Nat Commun, 2018, 9(1):4462.
[23] García-Lezana T, Raurell I, Bravo M, et al. Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis[J]. Hepatology, 2018, 67(4):1485-1498.
[24] Alisi A, Carsetti R, Nobili V. Pathogen- or damage-associated molecular patterns during nonalcoholic fatty liver disease development[J]. Hepatology, 2011, 54(5):1500-1502.
[25] Guilloteau P, Martin L, Eeckhaut V, et al. From the gut to the peripheral tissues: the multiple effects of butyrate[J]. Nutr Res Rev, 2010, 23(2):366-384.
[26] Park JS, Lee EJ, Lee JC, et al. Anti-inflammatory effects of short chain fatty acids in IFN-gamma-stimulated RAW 264.7 murine macrophage cells: involvement of NF-kappaB and ERK signaling pathways[J]. Int Immunopharmacol, 2007, 7(1):70-77.
[27] Jun JC, Cathrin S, Engstler AJ, et al. Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH)[J]. Br J Nutr, 2015, 114(11):1745-1755.
[28] Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis[J]. Science, 2013, 341(6145):569-573.
[29] Guilloteau P, Martin L, Eeckhaut V, et al. From the gut to the peripheral tissues: the multiple effects of butyrate[J]. Nutr Res Rev, 2010, 23(2):366-384.
[30] Zhang Q, Wu Y, Wang J, et al. Accelerated dysbiosis of gut microbiota during aggravation of DSS-induced colitis by a butyrate-producing bacterium[J]. Sci Rep, 2016, 6:27572.
[31] Pl?ger S, Stumpff F, Penner GB, et al. Microbial butyrate and its role for barrier function in the gastrointestinal tract[J]. Ann N Y Acad Sci, 2012, 1258:52-59.
[32] Park JS, Lee EJ, Lee JC, et al. Anti-inflammatory effects of short chain fatty acids in IFN-gamma-stimulated RAW 264.7 murine macrophage cells: involvement of NF-kappaB and ERK signaling pathways[J]. Int Immunopharmacol, 2007, 7(1):70-77.
[33] Jin CJ, Sellmann C, Engstler AJ, et al. Supplementation of sodium butyrate protects mice from the development of nonalcoholic steatohepatitis (NASH) [J]. Br J Nutr, 2015, 114(11):1745- 1755.
[34] Kubes P, Mehal WZ. Sterile inflammation in the liver[J]. Gastroenterology, 2012, 143(5):1158-1172.

备注/Memo

备注/Memo:
[ 基金项目] 广东省科技计划项目(2015A030302085,2016A020212022)
[ 通信作者] 张发明,E-mail: fzhang@njmu.edu.cn;陈羽,E-mail: yuchen@gdpu.edu.cn
更新日期/Last Update: 2019-09-15